We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Artificial Intelligence Test Determines Risk of Bowel Cancer Recurrence After Surgery

By LabMedica International staff writers
Posted on 02 Aug 2024
Print article
Image: An AI bowel cancer test can tell whether patients need chemotherapy (Photo courtesy of Shutterstock)
Image: An AI bowel cancer test can tell whether patients need chemotherapy (Photo courtesy of Shutterstock)

Bowel cancer, commonly referred to as colorectal cancer, can develop anywhere in the large bowel, including the colon and rectum. It ranks among the most prevalent cancers globally, with 1.9 million new cases recorded in 2020. The current protocols for determining the need for chemotherapy for patients with early-stage bowel cancer are not consistently reliable. As a result, some patients receive chemotherapy unnecessarily, while others who might benefit from it do not receive it and may face cancer recurrence. This decision is particularly challenging for stage II colon cancer, where the risk of recurrence post-surgery is generally lower. Now, a new artificial intelligence (AI) test can predict the risk of recurrence in bowel cancers, potentially helping patients avoid unnecessary chemotherapy. This test employs an AI algorithm to measure the concentration of immune cells known as CD3 in tumors at the early stages of bowel cancer.

Previous studies have indicated that bowel and rectal tumors with a higher presence of CD3 immune cells have a reduced likelihood of recurrence after surgical removal. This is attributed to the ability of CD3 cells to combat cancer, aiding the body's response to the disease. In the latest study by researchers at the University of Leeds (West Yorkshire, UK), the CD3 Score test effectively identified which stage II cancers were more prone to recurrence within five years post-surgery. This information could aid clinicians in determining the need for additional treatments, such as chemotherapy. The study analyzed tissue samples from 868 bowel tumors classified as stage II and III to quantify the CD3 cells present within the tumors.

The AI algorithm developed by the research team calculated a 'CD3 Score' based on the distribution of CD3 cells throughout the tumor. Tumors assigned a high-risk CD3 Score displayed fewer immune cells, whereas those with a low-risk score exhibited a higher number of immune cells. Tumors categorized with a high-risk CD3 Score were three times more likely to recur within five years of surgery compared to those with a low-risk score. Although chemotherapy reduced recurrence rates in both groups, the study further revealed that patients with fewer immune cells gained the most from chemotherapy. These findings, published in the Journal of Clinical Oncology, could assist doctors in making informed decisions about administering chemotherapy following bowel cancer surgery.

“This has the potential to be the most important test patients with early-stage bowel cancer ask for. It’s fast, accurate and simple, and we hope it will make conversations about chemotherapy after surgery much more straightforward for patients and their doctors,” said lead author Dr. Christopher Williams, Cancer Research UK Clinical Trials Research Fellow in the University of Leeds’ School of Medicine.

Related Links:
University of Leeds

New
Gold Member
Troponin T QC
Troponin T Quality Control
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Whole Blood-Based Controls
Lyphochek Hemoglobin A1C Linearity Set
New
Calprotectin One Step Card Test
CerTest Calprotectin

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The new platelet-centric scoring system predicts platelet hyperreactivity and related risk of cardiovascular events (Photo courtesy of Shutterstock)

Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke

Platelets, which are cell fragments circulating in the blood, play a critical role in clot formation to stop bleeding. However, in some individuals, platelets can become "hyperreactive," leading to excessive... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: The Accelerate WAVE system delivers rapid AST directly from positive blood culture bottles (Photo courtesy of Accelerate Diagnostics)

Rapid Diagnostic System to Deliver Same-Shift Antibiotic Susceptibility Test Results

The World Health Organization estimates that sepsis impacts around 49 million people worldwide each year, resulting in roughly 11 million deaths, with about 1.32 million of these deaths directly linked... Read more

Industry

view channel
Image: Roche has expanded its digital pathology open environment with more than 20 AI algorithms (Photo courtesy of Roche)

Roche Expands Digital Pathology Open Environment with Integration of Advanced AI Algorithms from New Collaborators

Roche (Basel, Switzerland) has expanded its digital pathology open environment by integrating over 20 advanced artificial intelligence (AI) algorithms from eight new collaborators. These strategic collaborations... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.